# Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)

> **NCT02125877** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 173 (actual)

## Conditions studied

- Chronic Iron Overload Due to Transfusion-dependant Anemias

## Interventions

- **DRUG:** Deferasirox dispersible tablet
- **DRUG:** Defearisox film-coated tablet

## Key facts

- **NCT ID:** NCT02125877
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-07-08
- **Primary completion:** 2016-02-24
- **Final completion:** 2016-02-24
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2017-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02125877

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02125877, "Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT02125877. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*